BMY · Insider Trading
Bristol-Myers Squibb Co.
Every open-market purchase and sale reported by BMY officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Cari Gallman | EVP, General Counsel | MIXED | +2,227 | −$142.60K |
| 2026-10-02 | Peter J Arduini | Director | A | +560 deriv. | — |
| 2026-10-02 | Michael R. McMullen | Director | A | +560 deriv. | — |
| 2026-10-02 | Phyllis R Yale | Director | A | +560 deriv. | — |
| 2026-10-02 | Theodore R. Samuels II | Director | A | +821 deriv. | — |
| 2026-10-02 | Derica W Rice | Director | A | +620 deriv. | — |
| 2026-09-10 | Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | Sell | −6,249 | −$403.50K |
| 2026-09-03 | Bartie Wendy Short | EVP, Corporate Affairs | MIXED | +603 | +$40.35K |
| 2026-08-26 | Phil M Holzer | SVP and Controller | Sell | −500 | −$33.75K |
| 2026-08-04 | Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | MIXED | +24,997 | −$1.71M |
| 2026-08-04 | Cari Gallman | EVP, General Counsel | MIXED | +518 | −$35.46K |
| 2026-07-02 | Phyllis R Yale | Director | A | +607 deriv. | — |
| 2026-07-02 | Derica W Rice | Director | A | +672 deriv. | — |
| 2026-07-02 | Michael R. McMullen | Director | A | +607 deriv. | — |
| 2026-07-02 | Theodore R. Samuels II | Director | A | +889 deriv. | — |
| 2026-07-02 | Peter J Arduini | Director | A | +607 deriv. | — |
| 2026-06-16 | Julia A Haller | Director | M | +20,460 | +$1.10M |
| 2026-06-05 | Bartie Wendy Short | EVP, Corporate Affairs | MIXED | +4,164 | −$212.09K |
| 2026-05-05 | Adam Lenkowsky | EVP, Chief Commercial Officer | MIXED | +571 | −$34.87K |
| 2026-04-02 | Peter J Arduini | Director | A | +577 deriv. | — |
| 2026-04-02 | Michael R. McMullen | Director | A | +577 deriv. | — |
| 2026-04-02 | Derica W Rice | Director | A | +638 deriv. | — |
| 2026-04-02 | Theodore R. Samuels II | Director | A | +845 deriv. | — |
| 2026-04-02 | Phyllis R Yale | Director | A | +577 deriv. | — |
| 2026-04-02 | David V Elkins | EVP, Chief Financial Officer | Sell | −30,000 | −$1.85M |
| 2026-04-02 | Karin Shanahan | EVP, Chief Supply Chain & Ops | MIXED | +1,615 | −$104.45K |
| 2026-03-12 | David V Elkins | EVP, Chief Financial Officer | MIXED | +21,869 | −$968.93K |
| 2026-03-12 | Christopher S. Boerner | Chief Executive Officer | MIXED | +20,269 | −$1.28M |
| 2026-03-12 | Ahn Amanda Poole | EVP, Chief People Officer | MIXED | +1,898 | −$119.78K |
| 2026-03-12 | Cari Gallman | EVP, General Counsel | MIXED | +2,065 | −$130.18K |
| 2026-03-12 | Lynelle Hoch | President, Cell Therapy Org. | MIXED | +3,499 | −$83.64K |
| 2026-03-12 | Phil M Holzer | SVP and Controller | MIXED | +2,395 | −$81.66K |
| 2026-03-12 | Adam Lenkowsky | EVP, Chief Commercial Officer | MIXED | +6,696 | −$421.81K |
| 2026-03-12 | Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | MIXED | +8,933 | −$395.78K |
| 2026-03-12 | Robert M Plenge | EVP, Chief Research Officer | MIXED | +5,689 | −$272.69K |
| 2026-03-12 | Karin Shanahan | EVP, Chief Supply Chain & Ops | MIXED | +7,408 | −$466.61K |
| 2026-03-12 | Bartie Wendy Short | EVP, Corporate Affairs | MIXED | +2,248 | −$76.67K |
| 2026-03-12 | Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | A | +65,306 deriv. | — |
| 2026-03-12 | Hiroshi Chris Shibutani | EVP, Chief Strategy Officer | A | +19,592 deriv. | — |
| 2026-03-12 | Benjamin Hickey | President, RayzeBio Org. | A | +28,572 deriv. | — |
| 2026-03-03 | Benjamin Hickey | President, RayzeBio Org. | MIXED | +1,614 | −$104.28K |
| 2026-02-03 | Peter J Arduini | Director | A | +3,996 deriv. | — |
| 2026-02-03 | Deepak Bhatt | Director | A | +3,996 deriv. | — |
| 2026-02-03 | Julia A Haller | Director | A | +3,996 deriv. | — |
| 2026-02-03 | Medina Manuel Hidalgo | Director | A | +3,996 deriv. | — |
| 2026-02-03 | Michael R. McMullen | Director | A | +3,996 deriv. | — |
| 2026-02-03 | Paula A Price | Director | A | +3,996 deriv. | — |
| 2026-02-03 | Derica W Rice | Director | A | +3,996 deriv. | — |
| 2026-02-03 | Theodore R. Samuels II | Director | A | +3,996 deriv. | — |
| 2026-02-03 | Karen H Vousden | Director | A | +3,996 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Sandra Leung | EVP, General Counsel | 457,732 | $28.24M |
| Christopher S. Boerner | Chief Executive Officer | 172,821 | $10.66M |
| David V Elkins | EVP, Chief Financial Officer | 164,023 | $10.12M |
| Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 83,513 | $5.15M |
| Theodore R. Samuels II | Director | 35,500 | $2.19M |
| Julia A Haller | Director | 34,079 | $2.10M |
| Karin Shanahan | EVP, Chief Supply Chain & Ops | 27,345 | $1.69M |
| Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 25,816 | $1.59M |
| Adam Lenkowsky | EVP, Chief Commercial Officer | 25,684 | $1.58M |
| Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | 18,748 | $1.16M |
| Robert M Plenge | EVP, Chief Research Officer | 18,675 | $1.15M |
| Benjamin Hickey | President, RayzeBio Org. | 18,344 | $1.13M |
| Phil M Holzer | SVP and Controller | 16,862 | $1.04M |
| Cari Gallman | EVP, General Counsel | 15,876 | $979.39K |
| Bartie Wendy Short | EVP, Corporate Affairs | 12,684 | $782.48K |
| Ahn Amanda Poole | EVP, Chief People Officer | 6,228 | $384.26K |
| Lynelle Hoch | President, Cell Therapy Org. | 5,243 | $323.44K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BMY quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.